Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y9YN
|
|||
| Former ID |
DNCL002771
|
|||
| Drug Name |
Velimogene aliplasmid
|
|||
| Synonyms |
Allovectin (TN)
Click to Show/Hide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 3 | [1] | |
| Company |
Vical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HLA class I antigen B-7 (HLA-B) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00050388) Phase II Trial of Allovectin-7 for Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.